Laboratorios Rovi : Q2 2022 results beat consensus expectations despite the slowdown in sales. Guidance for FY maintained
>Sales growth slowdown in Q2 2022, but in line with expectations - Total revenues increased 9% y-o-y in Q1 2022 reaching € 175m, in line with estimates but showing a slower growth than in previous quarter (vs € 206m sales reported in Q1 2022 or +58% y-o-y and +57% in Q4 2021) due to a slowdown in toll manufacturing sales to Moderna for its mRNA Covid vaccine vs previous quarters (sales of toll manufacturing +21% y-o-y to € 71m vs +167% growth posted in Q1 2022 or € 95...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.